Health Canada approves Truseltiq for cholangiocarcinoma under Project Orbis.
Helsinn Group and BridgeBio Pharma announced that Health Canada has approved Truseltiq (infigratinib), a small molecule kinase inhibitor that targets fibroblast growth factor receptor (FGFR), under under Project Orbis, the Notice of Compliance with Conditions (NOC/c) policy, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a FGFR2 fusion or other rearrangement.